What is the domestic market price of ritexitinib?

Ritlecitinib is a highly selective oral Janus kinase (JAK) inhibitor. Preparations, mainly targeting JAK3 and TEC family kinases, for the treatment of alopecia areata (Alopecia Areata). Alopecia areata is an autoimmune disease caused by the immune system attacking hair follicles, causing hair or body hair to fall out. Ritexitinib reduces the attack of immune cells on hair follicles by inhibiting the activity of the JAK-STAT signaling pathway, thereby protecting hair follicles and promoting hair regeneration.

In clinical trials, ritexitinib has shown significant efficacy, especially in patients with moderate to severe alopecia areata. Study data showed that after 24 weeks of treatment, many patients experienced significant increases in hair coverage and the drug was well tolerated. Most adverse reactions are mild to moderate, and common side effects include upper respiratory tract infection, headache, gastrointestinal discomfort, etc.

Ritexitinib is currently on the market in China and has become a new option for domestic patients with alopecia areata. Although the drug has not yet been included in the national medical insurance list, patients can purchase it at regular domestic pharmacies or hospitals. The selling price of ritexitinib in China is about more than 3,000 yuan per month. The specific price may vary slightly depending on the region and hospital. Patients are advised to consult a doctor before taking medication for detailed treatment plans and medication instructions, and also consult local pharmacies before purchasing medication to obtain the latest price information.

Despite its higher price, the launch of ritexitinib provides a new treatment option for patients with alopecia areata. It is especially suitable for patients who have no obvious response to traditional treatments. Through stable and continuous medication, it is expected to significantly improve the patient's quality of life. In the future, with the accumulation of more clinical data and increasing experience in use, ritexitinib may be included in the medical insurance catalog, providing patients with broader treatment protection and further reducing their economic burden.